🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

Showing page 53 of 857 · Phase 3 first, then by program name

  1. Delayed and extended release mesalazine

    Takeda

    Colitis, Ulcerative

    phase 3 small molecule completed

    1 trial

  2. Dendritic cell immunotherapy

    NORTHWEST BIOTHERAPEUTICS INC

    Glioblastoma Multiforme

    phase 3 small molecule active

    1 trial

  3. Dendritic cell immunotherapy

    NORTHWEST BIOTHERAPEUTICS INC

    Prostate Cancer

    phase 3 small molecule terminated

    1 trial

  4. Denifanstat

    Sagimet Biosciences

    MASH

    phase 3 small molecule terminated

    1 trial

  5. Denosumab

    Amgen

    Cancer

    phase 3 small molecule completed

    1 trial

  6. Depigoid Grass-Mix (1000 DPP/ml), Conjunctival Provocation Test Grass-Mix LETI 30 HEP/ml, The placebo to be used in the clinical trial is the solvent used in the investigational medicinal products’ (IMPs) formulation. The resulting product is a suspension., Depigoid FORTE Grass-Mix (3000 DPP/ml)

    Lacuna Pharma Pty Ltd

    Allergic rhinoconjunctivitis with or without controlled asthma

    phase 3 small molecule active

    1 trial

  7. Depot naltrexone

    BRIGHT MINDS BIOSCIENCES INC.

    Opiate Addiction

    phase 3 small molecule completed

    1 trial

  8. Deramiocel (CAP-1002)

    CAPRICOR THERAPEUTICS, INC.

    Muscular Dystrophies

    phase 3 mab active

    1 trial

  9. Descovy or Truvada

    BRIGHT MINDS BIOSCIENCES INC.

    HIV Infections

    phase 3 small molecule completed

    1 trial

  10. Desmopressin

    Ferring Pharmaceuticals

    Nocturia

    phase 3 small molecule completed

    1 trial

  11. Deucravacitinib

    Bristol-Myers Squibb

    Sjögren's Syndrome

    phase 3 small molecule active

    1 trial

  12. Deucravacitinib placebo 3 mg film-coated tablets oral use, Deucravacitinib placebo 6 mg film-coated tablets oral use, deucravacitinib, deucravacitinib

    Bristol-Myers Squibb Australia Pty Ltd

    Sjogren's syndrome

    phase 3 small molecule active

    1 trial

  13. Deutetrabenazine

    Teva Pharma GmbH

    Huntington Disease

    phase 3 small molecule active

    1 trial

  14. Dexa 8 mg inject JENAPHARM Injektionslösung, VELCADE 3.5 mg powder for solution for injection, Dexamethason 8 mg GALEN® Tabletten, Dexamethasone Tablets BP 2.0mg, Dexamethasone 2mg Tablets, Dexa-ratiopharm® 8 mg Injektionslösung, DARZALEX 20 mg/mL concentrate for solution for infusion, Dexamethason 8 mg JENAPHARM®

    GlaxoSmithKline

    Multiple Myeloma

    phase 3 small molecule active

    1 trial

  15. Dexamethason 8 mg GALEN® Tabletten, Imnovid 1 mg hard capsules, Dexamethasone 2mg Tablets, Dexamethason 8 mg JENAPHARM®, Dexamethasone Tablets BP 2.0mg, Imnovid 4 mg hard capsules

    GlaxoSmithKline

    Relapsed/Refractory Multiple Myeloma

    phase 3 small molecule active

    1 trial

  16. Dexamethason CF 20 mg/ml, injectievloeistof, Imnovid 4 mg hard capsules, ELOTUZUMAB, VELCADE 3.5 mg powder for solution for injection, IXAZOMIB , Dexamethason 4 mg JENAPHARM®, Kyprolis 30 mg powder for solution for infusion, Imnovid 1 mg hard capsules, Imnovid 2 mg hard capsules, Imnovid 3 mg hard capsules, Revlimid 15 mg hard capsules, IXAZOMIB, idecabtagene vicleucel, DARZALEX 20 mg/mL concentrate for solution for infusion, Revlimid 10 mg hard capsules, IXAZOMIB, Revlimid 5 mg hard capsules, Revlimid 25 m

    Celgene Europe Limited

    Multiple myeloma (MM) with at least 2 prior therapies including an immunomodulatory (IMiD) compound and a proteasome inhibitor (PI) and demonstrated disease progression on or within 60 days of completion of the last therapy.

    phase 3 small molecule active

    1 trial

  17. Dexamethasone

    Amgen

    Relapsed Multiple Myeloma

    phase 3 small molecule completed

    1 trial

  18. Dexamethasone

    United Therapeutics Europe Ltd

    Shoulder Pain

    phase 3 small molecule terminated

    1 trial

  19. Dexamethasone

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Acute Respiratory Distress Syndrome (ARDS)

    phase 3 small molecule active

    1 trial

  20. Dexamethasone

    Quince Therapeutics

    Crohn's Disease

    phase 3 small molecule terminated

    1 trial

  21. Dexamethasone Tablets BP 2.0mg, Fortecortin® 2 mg Tabletten, Lenalidomide Accord 15 mg hard capsules, CARVYKTI 3.2 × 10^6 – 1.0 × 10^8 cells dispersion for infusion, Lenalidomide Mylan 5 mg hard capsules, Lenalidomide Mylan 20 mg hard capsules, VELCADE 3.5 mg powder for solution for injection, Lenalidomide Mylan 20 mg hard capsules, Lenalidomide Accord 10 mg hard capsules, Lenalidomide Accord 2.5 mg hard capsules, FLUDARABINE , Lenalidomide Mylan 15 mg hard capsules, Lenalidomide Accord 10 mg hard capsules

    Janssen-Cilag International N.V.

    Multiple Myeloma

    phase 3 small molecule active

    1 trial

  22. Dexamethasone sodium phosphate

    Quince Therapeutics

    Ataxia Telangiectasia

    phase 3 small molecule completed

    2 trials

  23. Dexamethasone sodium phosphate for encapsulation into autoerythrocytes

    Quince Therapeutics

    Ataxia Telangiectasia (A-T)

    phase 3 small molecule active

    1 trial

  24. Dexlansoprazole

    Takeda

    Erosive Esophagitis

    phase 3 small molecule terminated

    2 trials

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources